The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
